Please assess the completion status of the following clinical trial:

Trial Title: Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed VIN (only usual type, formerly VIN 2-3)~* Visible, measurable lesion(s)~* Contraception (for premenopausal women)~Exclusion Criteria:~* Evidence of invasion~* History of cancer or severe inflammatory dermatosis of the vulva~* Pregnancy, lactation~* Immunodeficiency~* Any treatment for VIN within the previous three months~* Known hypersensitivity to imiquimod

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Primary Imiquimod (Type: EXPERIMENTAL): Treatment with imiquimod will be patient self-administered for a period of 4 months with possible extension to 6 months. A thin layer of imiquimod cream should be applied to the lesion and remain overnight without a cover. Application will be once a week for 2 weeks, then twice a week the following 2 weeks and, if tolerated, 3 times a week for the last weeks. In case of severe side-effects the number of applications can be reduced; a treatment-free period of no more than 1 week is permitted
- Primary surgery (Type: ACTIVE_COMPARATOR): The type of surgery (excision or ablation) will be based on clinical findings and surgeon's judgement. After excision the specimen will be histologically analyzed to assess resection margins and rule out invasion.

Based on this trial design, predict the completion outcome and termination type (if applicable).